EUVIMEDOpdag EUVIMED
Crossref

Predictors of treatment‐response to caffeine combination products, acetaminophen, acetylsalicylic acid (aspirin), and nonsteroidal anti‐inflammatory drugs in acute treatment of episodic migraine

Ali Ezzati iD, Kristina M Fanning, Michael L Reed, Richard B Lipton

Headache: The Journal of Head and Face Pain · 2023-03 · 63 (3) · 342-352

DOI: 10.1111/head.14459 ↗

At a glance

Journal article in Headache: The Journal of Head and Face Pain, published online on 2023-02-07. Written by Ali Ezzati and 3 co-authors. Institution: Department of Neurology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA. Major MEDLINE topics: Acetaminophen, Migraine Disorders. Cited 11 times so far (Crossref); 39 references. Funded by: GlaxoSmithKline Plc (GSK), GlaxoSmithKline.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objective

To identify predictors of acute treatment optimization for migraine with “over‐the‐counter” (OTC) or prescription nonsteroidal anti‐inflammatory drugs (NSAIDs) as well as other widely used OTCs including acetaminophen, caffeine combination products (CCP), and acetylsalicylic acid (ASA, aspirin) among people with episodic migraine and to develop models that predict treatment response to each class of OTCs.

Background

Efficacy of acute OTC medications for migraine varies greatly. Identifying predictors of treatment response to particular classes of medication is a step toward evidence‐based personalized therapy.

Methods

For this prediction model development study, we used data from 2224 participants from the American Migraine Prevalence and Prevention (AMPP) study who were aged ≥18 years, met criteria for migraine, had

Subjects

MeSH terms (MEDLINE)

AcetaminophenMigraine DisordersMaleHumansFemaleAdolescentAdultMiddle AgedAspirinCaffeineHyperalgesiaAnti-Inflammatory Agents, Non-SteroidalNonprescription Drugs

Author keywords

acetaminophencaffeine combination productsepisodic migrainenonsteroidal anti-inflammatory drugstreatment response

Substances

AcetaminophenAspirinCaffeineAnti-Inflammatory Agents, Non-SteroidalNonprescription Drugs

Authors and institutions

  • Department of Neurology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.
  • Mist Research, Wilmington, North Carolina, USA.
  • Vedanta Research, Chapel Hill, North Carolina, USA.

ORCID profiles: Ali Ezzati

Funding

  • GlaxoSmithKline Plc (GSK)
  • GlaxoSmithKline

Cite

APA

Ezzati, A., Fanning, K. M., Reed, M. L., & Lipton, R. B. (2023). Predictors of treatment‐response to caffeine combination products, acetaminophen, acetylsalicylic acid (aspirin), and nonsteroidal anti‐inflammatory drugs in acute treatment of episodic migraine. Headache: The Journal of Head and Face Pain, 63(3), 342-352. https://doi.org/10.1111/head.14459

Vancouver

Ezzati A, Fanning KM, Reed ML, Lipton RB. Predictors of treatment‐response to caffeine combination products, acetaminophen, acetylsalicylic acid (aspirin), and nonsteroidal anti‐inflammatory drugs in acute treatment of episodic migraine. Headache: The Journal of Head and Face Pain. 2023;63(3):342-352. doi:10.1111/head.14459

BibTeX
@article{Ezzati2023,
  author = {Ezzati, Ali and Fanning, Kristina M and Reed, Michael L and Lipton, Richard B},
  title = {Predictors of treatment‐response to caffeine combination products, acetaminophen, acetylsalicylic acid (aspirin), and nonsteroidal anti‐inflammatory drugs in acute treatment of episodic migraine},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2023},
  volume = {63},
  number = {3},
  pages = {342--352},
  doi = {10.1111/head.14459}
}
Start for free →